KRT31 Antibody

What is KRT31 and what is its biological significance?

KRT31 (Keratin 31), also known as K1H1, is a type I cuticular hair keratin protein that belongs to the intermediate filament family. It has a calculated molecular weight of 47,237 Da and is primarily expressed in scalp tissue but absent in hairless skin . KRT31 is abundantly expressed in the differentiating cortex of growing (anagen) hair and is specifically restricted to the keratinocytes of the hair cortex, with no expression in the inner root sheath or medulla . As an essential component of the inner root sheath of hair follicles, KRT31 contributes to the structural integrity and mechanical properties of hair shafts . Like other keratins, KRT31 forms heterodimeric complexes with type II keratins (particularly KRT85) that assemble into polymeric fiber proteins, creating the cytoskeletal framework that supports hair structure .

How do KRT31 mutations affect hair structure and development?

Recent research has identified a nonsense variant in KRT31 (c.1081G>T; p.(Glu361*)) associated with autosomal dominant monilethrix, a rare hereditary hair disorder characterized by beaded hair shaft structure and increased hair fragility . This mutation leads to the abolition of both the last three amino acids of the 2B subdomain and the complete C-terminal tail domain of the protein . When co-expressed with its binding partner keratin 85, the truncated KRT31 is still expressed, albeit at lower levels than the wildtype protein . Importantly, immunofluorescence analysis revealed that the mutated KRT31 displays altered cytoskeletal localization, forming vesicular-like structures in the cell cytoplasm near the cell membrane rather than maintaining normal cytoplasmic distribution . This disruption in localization impairs the protein's function and contributes to the monilethrix phenotype.

What genomic and protein characteristics define KRT31?

KRT31 has specific genomic and protein characteristics that are important for researchers to consider:

What criteria should researchers use when selecting a KRT31 antibody?

When selecting a KRT31 antibody for research applications, several critical factors should be considered to ensure experimental success. First, evaluate the antibody's specificity through validation data that demonstrates selective binding to KRT31 without cross-reactivity to other keratin family members . Second, consider the species reactivity - available antibodies have been validated for human and mouse samples . Third, match the antibody format to your application needs - antibodies are available in various formats including polyclonal (which may provide broader epitope recognition) and monoclonal (which may offer higher specificity) .

The immunogen used to generate the antibody is also crucial - some antibodies target synthetic peptides derived from human KRT31 at amino acid range 10-90, while others target recombinant fragment proteins within the 150-400 amino acid range . Finally, verify that the antibody has been validated for your specific application (Western blot, ELISA, immunocytochemistry/immunofluorescence) through published validation data or manufacturer testing .

How should researchers validate KRT31 antibody specificity?

Thorough validation of KRT31 antibody specificity is essential for reliable research results. A comprehensive validation protocol should include:

• Positive and negative control tissues: Test the antibody on scalp tissue (positive control) and hairless skin (negative control) based on known KRT31 expression patterns .

• Western blot analysis: Perform Western blot with cell lysates known to express KRT31 (such as HeLa cells) to confirm a single band at the expected molecular weight of approximately 47 kDa . Include a negative control lysate from cells that do not express KRT31.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide before application to verify that this prevents antibody binding, confirming specificity for the target epitope .

• Genetic validation: Test the antibody in samples with KRT31 knockdown or knockout to confirm reduced or absent signal. Similarly, overexpression systems can confirm increased signal with increased target expression.

• Cross-reactivity testing: Test against closely related keratin family members to ensure the antibody does not recognize other keratin proteins, particularly other type I hair keratins.

Manufacturers like Boster Bio validate their antibodies through multiple methods including Western blot, IHC, ICC, immunofluorescence, and ELISA with known positive and negative samples , but independent validation in your specific experimental system is still recommended.

What are the optimal conditions for using KRT31 antibodies in Western blot?

For optimal Western blot performance with KRT31 antibodies, researchers should follow these methodological guidelines:

• Sample preparation: Extract proteins from tissues or cells using standard lysis buffers containing protease inhibitors. Hair samples may require specialized extraction protocols using urea-based buffers to solubilize keratin proteins.

• Protein loading: Load 20-30 μg of total protein per lane, as demonstrated in validated protocols with HeLa cell lysates .

• Gel electrophoresis: Use 10% SDS-PAGE gels for optimal separation around the 47 kDa range where KRT31 is expected .

• Transfer conditions: Transfer to PVDF or nitrocellulose membranes using standard protocols (wet transfer recommended for consistent results with intermediate filament proteins).

• Blocking: Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Primary antibody dilution: Begin with the manufacturer's recommended dilution range (e.g., 1:500-2000 for Boster Bio antibody A13044 or 1:5000 for Abcam antibody ab111730) . Optimize as needed for your specific conditions.

• Incubation conditions: Incubate with primary antibody overnight at 4°C for optimal binding.

• Detection: Use appropriate secondary antibodies and detection systems compatible with your primary antibody host species (typically rabbit for available KRT31 antibodies).

• Expected result: A single band at approximately 47 kDa for wild-type KRT31. For mutant variants like the truncated p.(Glu361*) form, a slightly smaller band may be detected .

How can KRT31 antibodies be effectively used in immunofluorescence studies?

Immunofluorescence studies using KRT31 antibodies require careful optimization for clear visualization of the cytoskeletal network. Follow these methodological recommendations:

• Sample preparation: Fix cells with 4% paraformaldehyde (10 minutes) or ice-cold methanol (10 minutes), with methanol fixation being preferred for cytoskeletal proteins like KRT31 .

• Permeabilization: If using paraformaldehyde fixation, permeabilize with 0.1-0.5% Triton X-100 in PBS for 5-10 minutes (not necessary with methanol fixation).

• Blocking: Block with 1-5% normal serum (from the same species as the secondary antibody) in PBS with 0.1% Tween-20 for 30-60 minutes.

• Primary antibody: Dilute KRT31 antibody according to manufacturer recommendations. For comparative studies of wild-type and mutant KRT31, identical conditions should be used to accurately assess differences in localization patterns .

• Co-staining options: Consider co-staining with markers for different cellular compartments (e.g., cell membrane markers) to better visualize the altered localization of mutant KRT31, which tends to form vesicular-like structures near the cell membrane instead of the normal cytoplasmic distribution .

• Expected patterns:

  • Wild-type KRT31: Filamentous cytoplasmic staining pattern typical of intermediate filaments

  • Mutant KRT31 (e.g., p.(Glu361*)): Vesicular-like structures predominantly near the cell membrane

• Controls: Include negative controls (omitting primary antibody) and positive controls (cells known to express KRT31, such as HeLa cells) .

What considerations are important for ELISA applications with KRT31 antibodies?

When using KRT31 antibodies in ELISA applications, researchers should consider these methodological factors:

• Antibody dilution optimization: Begin with the manufacturer's recommended dilution range (e.g., 1:5000-20000 for Boster Bio antibody A13044) and perform a dilution series to determine optimal concentration for your specific experimental conditions.

• Sample preparation: For detecting KRT31 in complex biological samples, consider pre-clearing samples to reduce background and using appropriate blocking agents to minimize non-specific binding.

• Standard curve generation: For quantitative analysis, develop a standard curve using recombinant KRT31 protein at known concentrations.

• Cross-reactivity controls: Include samples containing related keratin family members to verify specificity, particularly important when analyzing hair samples that contain multiple keratin types.

• Assay validation parameters: Determine the limit of detection, range of linearity, and reproducibility of your ELISA protocol with your specific KRT31 antibody before proceeding with experimental samples.

• Sandwich ELISA considerations: When developing sandwich ELISA, use antibodies targeting different epitopes of KRT31 to prevent steric hindrance. Pairs of antibodies targeting the N-terminal region (e.g., AA range 10-90) and mid-region (e.g., AA range 150-400) may be particularly effective .

How are KRT31 antibodies used to study monilethrix and other hair disorders?

KRT31 antibodies have become valuable tools in studying monilethrix and other hair disorders, particularly following the recent discovery of a nonsense variant in KRT31 as a cause of autosomal dominant monilethrix . These antibodies enable researchers to:

• Detect protein expression alterations: KRT31 antibodies can be used in Western blot analysis to compare expression levels between normal and affected individuals. Research has shown that truncated KRT31 (p.(Glu361*)) is expressed at lower levels than wild-type KRT31 when co-expressed with keratin 85 .

• Visualize subcellular localization changes: Immunofluorescence studies with KRT31 antibodies have revealed critical insights into monilethrix pathogenesis, demonstrating that mutant KRT31 has altered cytoskeletal localization, forming vesicular-like structures near the cell membrane rather than distributing throughout the cytoplasm .

• Examine hair shaft abnormalities: KRT31 antibodies can be used for immunohistochemical analysis of hair shaft cross-sections to evaluate protein distribution in the beaded structure characteristic of monilethrix.

• Study protein-protein interactions: Immunoprecipitation with KRT31 antibodies, followed by mass spectrometry or Western blot, can identify altered interactions between mutant KRT31 and its binding partners, particularly keratin 85 .

• Evaluate nonsense-mediated decay: RT-qPCR analysis combined with KRT31 antibody detection can determine whether mutations lead to mRNA decay or produce truncated proteins. In the case of the p.(Glu361*) variant, research showed no evidence for nonsense-mediated decay .

These approaches have contributed to understanding that the pathogenic mechanism of KRT31-associated monilethrix likely involves disruption of the keratin cytoskeleton due to altered protein localization rather than complete absence of the protein .

What molecular mechanisms link KRT31 mutations to hair fragility?

Recent research using KRT31 antibodies has helped elucidate the molecular mechanisms by which KRT31 mutations lead to hair fragility in monilethrix . The findings reveal several critical insights:

• Disruption of keratin filament formation: The p.(Glu361*) nonsense mutation in KRT31 leads to the abolition of both the last three amino acids of the 2B subdomain and the complete C-terminal tail domain of keratin 31 . These regions are crucial for proper filament assembly and stability.

• Altered protein localization: Immunofluorescence studies using KRT31 antibodies have shown that mutant keratin 31 exhibits abnormal subcellular localization, with vesicular-like structures forming in the cell cytoplasm near the cell membrane instead of the normal cytoskeletal distribution . This altered localization disrupts the structural integrity of the keratin network.

• Impaired disulfide bond formation: Structural biology analysis suggests that the truncation prevents the formation of essential disulfide bonds between keratin molecules . Normally, two keratin molecules as a heterodimer align their ends with other heterodimers through disulfide bonds. The stop mutation likely prevents this critical interaction .

• Reduced protein expression: While not completely absent, the truncated keratin 31 shows reduced expression compared to wild-type protein when co-expressed with its binding partner keratin 85 . This quantitative reduction may contribute to weakened structural support.

• Dominant negative effect: The presence of the mutant protein appears to disrupt the function of the remaining wild-type protein through a dominant negative mechanism, explaining the autosomal dominant inheritance pattern .

The combination of these molecular defects results in a weakened hair shaft structure with the characteristic beaded appearance and increased fragility observed in monilethrix patients.

How can researchers optimize co-immunoprecipitation studies with KRT31 antibodies?

Co-immunoprecipitation (Co-IP) with KRT31 antibodies presents unique challenges due to the insoluble nature of keratin intermediate filaments. For successful studies examining KRT31 interactions with binding partners like keratin 85, researchers should consider these methodological optimizations:

• Lysis buffer selection: Use specialized lysis buffers containing chaotropic agents (e.g., 8M urea) or high salt concentrations to solubilize keratin filaments, followed by stepwise dilution to allow refolding and maintain protein-protein interactions.

• Crosslinking approach: Consider implementing reversible protein crosslinking (e.g., with DSP or formaldehyde) prior to cell lysis to stabilize transient or weak interactions between KRT31 and its binding partners.

• Antibody selection: Choose KRT31 antibodies with epitopes outside the protein-protein interaction domains (particularly avoiding the rod domain) to prevent interference with binding partner interactions. Antibodies targeting the head domain are often ideal for Co-IP applications .

• Pre-clearing strategy: Implement rigorous pre-clearing of lysates using protein A/G beads to reduce non-specific binding, which is particularly important when working with highly abundant structural proteins like keratins.

• Negative controls: Include IgG controls matched to the host species of the KRT31 antibody, as well as controls with irrelevant target-specific antibodies, to distinguish specific from non-specific interactions.

• Elution conditions: Optimize elution conditions to effectively recover KRT31 complexes without denaturing binding partners. Consider native elution with competing peptides when possible.

• Verification strategy: Confirm results through reciprocal Co-IP (i.e., immunoprecipitate with antibodies against the suspected binding partner and blot for KRT31) and orthogonal methods such as proximity ligation assays.

This optimized approach can be particularly valuable for investigating how mutations in KRT31, such as the p.(Glu361*) variant, affect its interactions with binding partners in the context of hair disorders like monilethrix .

What considerations are important when using KRT31 antibodies in transgenic mouse models?

When utilizing KRT31 antibodies in transgenic mouse models, researchers should address several important considerations to ensure valid and reproducible results:

• Cross-reactivity verification: Although available KRT31 antibodies are reported to react with both human and mouse KRT31 , researchers should independently verify cross-reactivity and specificity in mouse tissues before proceeding with extensive studies.

• Expression pattern differences: Note that while human and mouse KRT31 share significant homology, there may be subtle differences in expression patterns between species. Use proper controls (wild-type littermates) and consider species-specific expression atlases when interpreting results.

• Background strain effects: The background strain of transgenic mice can influence hair phenotypes and keratin expression. Always use appropriate genetic controls matched for background strain when analyzing KRT31 expression or localization.

• Developmental timing: Consider developmental timing when analyzing KRT31 expression, as hair follicle cycles in mice differ from humans. Standardize analysis to specific hair growth phases (anagen, catagen, telogen) for comparable results.

• Genotype verification: For KRT31 knockout or mutant models, use antibodies targeting different epitopes than those affected by the genetic modification to verify genotype at the protein level. This is particularly important for nonsense mutations like p.(Glu361*) where truncated protein may still be expressed .

• Fixation optimization: Optimize fixation conditions specifically for mouse tissues, which may require different protocols than human samples. For hair follicles, consider specialized fixatives that preserve both structure and antigenicity of keratin proteins.

• Quantification approaches: Develop consistent quantification approaches for immunohistochemistry or immunofluorescence that account for hair cycle variability and follicle orientation in tissue sections.

These considerations become especially important when using KRT31 antibodies to validate mouse models of monilethrix or other hair disorders for translational research applications .

What are common issues with KRT31 antibody applications and their solutions?

Researchers working with KRT31 antibodies may encounter several technical challenges. Here are common issues and evidence-based solutions:

How should researchers approach comparing wild-type and mutant KRT31 in experimental systems?

• Expression system selection:

  • For in vitro studies, use cell lines that do not endogenously express KRT31 (to avoid background signal)

  • Consider hair follicle-derived keratinocytes for more physiologically relevant contexts

  • Ensure equal transfection efficiency between wild-type and mutant constructs using co-expressed reporter systems

• Antibody epitope considerations:

  • For truncation mutations like p.(Glu361*), use antibodies with epitopes upstream of the mutation site (N-terminal or central regions)

  • For comparative studies, ideally use the same antibody for both wild-type and mutant detection

  • When necessary, epitope-tag both constructs identically to enable direct comparison with anti-tag antibodies

• Quantification approaches:

  • Implement unbiased, automated quantification methods for immunofluorescence signal intensity and distribution

  • For Western blot, normalize to multiple loading controls and consider absolute quantification with purified standards

  • Account for potential differences in protein stability by examining both steady-state levels and protein turnover rates

• Co-expression studies:

  • Always co-express KRT31 (wild-type or mutant) with its binding partner keratin 85 for physiologically relevant results

  • Consider ratio experiments with varying proportions of wild-type and mutant KRT31 to model heterozygous patient scenarios

  • Use differentially tagged versions (e.g., GFP-tagged wild-type and RFP-tagged mutant) for co-localization studies

• Functional readouts:

  • Develop quantitative assays for filament stability (e.g., resistance to chemical disruption)

  • Assess mechanical properties of formed filaments through biophysical methods

  • Evaluate cytoskeletal network formation through high-resolution microscopy and 3D reconstruction

Research has demonstrated that the p.(Glu361*) mutation leads to altered cytoskeletal localization with vesicular-like structures forming near the cell membrane, contrasting with the normal cytoplasmic distribution of wild-type KRT31 . These differences in localization pattern provide a clear readout for comparative studies.

What emerging technologies might enhance KRT31 antibody applications in hair biology research?

Several cutting-edge technologies are poised to significantly advance KRT31 antibody applications in hair biology research:

• Super-resolution microscopy: Techniques such as STORM, PALM, and STED microscopy can resolve keratin filament structure at nanometer scale, enabling detailed visualization of how KRT31 mutations affect filament assembly and organization. This technology has already revealed previously undetectable structural anomalies in other intermediate filament disorders .

• Proximity proteomics: Methods like BioID or APEX2 labeling combined with KRT31 antibodies can identify novel interaction partners in living cells, helping map the complete keratin interactome in hair follicles. This may reveal unexpected binding partners beyond the known keratin 85 interaction .

• Single-cell analysis: Integrating KRT31 antibodies with single-cell technologies can map expression heterogeneity across different hair follicle cell populations and developmental stages, potentially identifying previously unrecognized roles in hair follicle differentiation.

• CRISPR-engineered cellular and animal models: Precise genome editing to introduce patient-specific KRT31 mutations (like p.(Glu361*)) will create more accurate disease models for antibody-based studies of pathogenesis mechanisms in monilethrix .

• Intrabodies and nanobodies: Development of cell-permeable antibody fragments against KRT31 could enable real-time visualization of keratin dynamics in living cells, offering insights into filament assembly, turnover, and response to mechanical stress.

• Antibody-drug conjugates for therapeutic development: While still theoretical, KRT31 antibodies conjugated to compounds that stabilize keratin filaments could potentially be developed as targeted therapeutics for monilethrix and related disorders.

• Spatial transcriptomics combined with immunohistochemistry: Correlating KRT31 protein localization with comprehensive spatial gene expression patterns may reveal regulatory networks controlling keratin expression in hair follicles.

These technological advances promise to transform our understanding of KRT31 biology and pathology, potentially leading to novel diagnostic approaches and therapeutic strategies for monilethrix and other hair disorders .